> The weak dollar and the loss of a key patent depressed Boehringer Ingelheim's full-year results; sales grew 3.6 percent, fed mostly by the 30 percent jump in its lung treatment Spiriva. Report [1]

> Less than a month after seeing its lead drug candidate go down in flames in a late-stage trial, Keryx Biopharmaceuticals announced plans to restructure, chopping its workforce in half as it reduces the company's burn rate. Report [2]

> A high-profile crew of biopharma execs are signing on to help promote the life sciences industry in the UK. Report [3]

> Ranbaxy Laboratories got Japanese regulators' blessing for its generic form of Pfizer's angina and blood-pressure med Norvasc. Report [4]

> Australian women with advanced breast cancer will have cheaper access to the GlaxoSmithKline treatment Tykerb as the national drug program adds it to the formulary. Report [5]

> TPG Capital, a U.S. private equity group, is plowing $800 million into SIA International, a Russian pharma distribution company, in exchange for a 50 percent stake. Report [6]

> A stolen Pfizer laptop contained personal info on 800 employees and contractors, including credit card numbers, addresses, and phone numbers; the burgled computer marks the fifth data breach at the drugmaker since January 2007. Report [7]

> Alzheimer's treatment Aricept may be useful for treating stroke and accident victims, aiding memory and concentration, a small study shows. Report [8]

> Funds from non-profit groups are flowing to biotech R&D. Report [9]

And Finally... The ever-growing blogosphere has a new voice--none other than FDA commissioner Andrew von Eschenbach. Report [10]